His primary scientific interests are in Internal medicine, Surgery, Oncology, Gemcitabine and Cancer. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. His Surgery research incorporates elements of Clinical trial and Oxaliplatin.
The Oncology study combines topics in areas such as Pharmacokinetics, Chemotherapy, Sorafenib, Epidermal growth factor receptor and Adenocarcinoma. His Gemcitabine research is multidisciplinary, relying on both Clinical endpoint and Pancreatic disease. His Cancer research is multidisciplinary, incorporating perspectives in Psychiatry and Mediation.
Malcolm J. Moore spends much of his time researching Internal medicine, Oncology, Surgery, Chemotherapy and Gemcitabine. The study of Internal medicine is intertwined with the study of Gastroenterology in a number of ways. His biological study spans a wide range of topics, including Cetuximab, Clinical endpoint, Randomized controlled trial and Phases of clinical research.
In his study, which falls under the umbrella issue of Chemotherapy, Pharmacokinetics is strongly linked to Toxicity. The concepts of his Gemcitabine study are interwoven with issues in Pancreas, Oxaliplatin, Erlotinib and Cisplatin. His Colorectal cancer research includes themes of Bevacizumab, Adjuvant therapy and Hazard ratio.
His primary areas of study are Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Surgery. His study on Cancer, Colorectal cancer, Chemotherapy and Adverse effect is often connected to In patient as part of broader study in Internal medicine. The Oncology study combines topics in areas such as Cancer centre, KRAS, Proportional hazards model and Pancreas.
His Pancreatic cancer study incorporates themes from Clinical trial, FOLFIRINOX, Mortality rate, Confidence interval and Adenocarcinoma. The concepts of his Gemcitabine study are interwoven with issues in Gastroenterology, Oxaliplatin, Erlotinib and Phases of clinical research. His research investigates the connection with Surgery and areas like Radiology which intersect with concerns in Lymph node, Retroperitoneal lymph node dissection and Lymph.
Malcolm J. Moore focuses on Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Gastroenterology. Hazard ratio, Proportional hazards model, Cancer, Paclitaxel and Clinical trial are the primary areas of interest in his Internal medicine study. His Oncology study combines topics from a wide range of disciplines, such as Cetuximab, Colorectal cancer, Nab-paclitaxel and Pancreas.
His Pancreatic cancer study integrates concerns from other disciplines, such as Chemotherapy, Retrospective cohort study, DNA mismatch repair, Confidence interval and Veliparib. His Gemcitabine study results in a more complete grasp of Surgery. His Gastroenterology research is multidisciplinary, incorporating elements of Pharmacokinetics and Deoxycytidine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H A Burris;M J Moore;J Andersen;M R Green.
Journal of Clinical Oncology (1997)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean.
The New England Journal of Medicine (2013)
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore;David Goldstein;John Hamm;Arie Figer.
Journal of Clinical Oncology (2007)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S Karapetis;Shirin Khambata-Ford;Derek J Jonker;Chris J O'Callaghan.
The New England Journal of Medicine (2008)
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz;John V. Cox;Charles Blanke;Lee S. Rosen.
The New England Journal of Medicine (2000)
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Christine M. Ribic;Daniel J. Sargent;Malcolm J. Moore;Malcolm J. Moore;Stephen N. Thibodeau.
The New England Journal of Medicine (2003)
Cetuximab for the Treatment of Colorectal Cancer
Derek J Jonker;Chris J O'Callaghan;Christos S Karapetis;John R Zalcberg.
The New England Journal of Medicine (2007)
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
I. F. Tannock;D. Osoba;M. R. Stockler;D. S. Ernst.
Journal of Clinical Oncology (1996)
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
Hans von der Maase;Lisa Sengelov;James T. Roberts;Sergio Ricci.
Journal of Clinical Oncology (2005)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent;Silvia Marsoni;Genevieve Monges;Stephen N. Thibodeau.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: